Tg Therapeutics (TGTX) Operating Leases (2019 - 2026)

Tg Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $6.6 million for Q1 2026.

• In Q1 2026, Operating Leases fell 16.09% year-over-year to $6.6 million; the TTM figure through Mar 2026 stood at $6.6 million (down 16.09% YoY), while the FY2025 annual figure was $7.0 million, down 13.67% from the prior year.
• Operating Leases was $6.6 million for Q1 2026 at Tg Therapeutics, down from $7.0 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $10.6 million in Q3 2022 to a low of $6.6 million in Q1 2026.
• Historically, Operating Leases has averaged $8.8 million across 5 years, with a median of $9.0 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Operating Leases advanced 5.61% in 2022, then dropped 16.09% in 2026.
• A 5-year view of Operating Leases shows it stood at $10.3 million in 2022, then dropped by 10.76% to $9.2 million in 2023, then dropped by 11.89% to $8.1 million in 2024, then retreated by 13.67% to $7.0 million in 2025, then retreated by 6.07% to $6.6 million in 2026.
• The last three Operating Leases figures came in at $6.6 million (Q1 2026), $7.0 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.